Most cited papers in Vascular Tumors and Angiosarcomas
What are the most cited papers in Vascular Tumors and Angiosarcomas?
The most cited paper in Vascular Tumors and Angiosarcomas is "Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth" (Michael S. O’Reilly, Thomas Boehm, Yuen Shing et al., 1997), with 4,521 citations. Next come "Vascular endothelial growth factor (VEGF) and its receptors" (3,520) and "Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial" (2,123).
Showing 50 of 100 papers. Every paper with more than 520 citations is listed.
| # | Paper | ||
|---|---|---|---|
| 1 | Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth Michael S. O’Reilly, Thomas Boehm, Yuen Shing et al. · Cell | 1997 | 4,521 |
| 2 | Vascular endothelial growth factor (VEGF) and its receptors Gera Neufeld, Tzafra Cohen, Stela Gengrinovitch et al. · The FASEB Journal | 1999 | 3,520 |
| 3 | Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial Winette T.A. van der Graaf et al. · The Lancet | May 2012 | 2,123 |
| 4 | Follow-up study of thymomas with special reference to their clinical stages Akira Masaoka, Yasumasa Monden, Kazuya Nakahara et al. · Cancer | Dec 1981 | 1,725 |
| 5 | VEGF-targeted therapy: mechanisms of anti-tumour activity Lee M. Ellis, Daniel J. Hicklin · Nature reviews. Cancer | 3 Jul 2008 | 1,683 |
| 6 | Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up Paolo Giovanni Casali et al. · Annals of Oncology | 28 Mar 2018 | 1,636 |
| 7 | Pten is essential for embryonic development and tumour suppression Antonio Di Cristofano, Bárbara Pesce, Carlos Cordon‐Cardo et al. · Nature Genetics | Aug 1998 | 1,532 |
| 8 | Tuberous Sclerosis Complex Diagnostic Criteria Update: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference Hope Northrup et al. · Pediatric Neurology | 19 Sep 2013 | 1,524 |
| 9 | Vascular Anomalies Classification: Recommendations From the International Society for the Study of Vascular Anomalies Michel Wassef, Francine Blei, Denise M. Adams et al. · PEDIATRICS | 10 Jun 2015 | 1,425 |
| 10 | The anti-angiogenic basis of metronomic chemotherapy Robert S. Kerbel, Barton A. Kamen · Nature reviews. Cancer | Jun 2004 | 1,409 |
| 11 | Epithelioid hemangioendothelioma a vascular tumor often mistaken for a carcinoma Sharon Whelan Weiss, Franz M. Enzinger · Cancer | Sep 1982 | 1,403 |
| 12 | Phosphorylation and Functional Inactivation of TSC2 by Erk Li Ma, Zhenbang Chen, Hediye Erdjument‐Bromage et al. · Cell | Apr 2005 | 1,274 |
| 13 | Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. Peter W. T. Pisters, Denis H. Y. Leung, James M. Woodruff et al. · Journal of Clinical Oncology | May 1996 | 1,228 |
| 14 | Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial Ian Robert Judson, Jaap Verweij, Hans A. J. Gelderblom et al. · The Lancet Oncology | 5 Mar 2014 | 1,195 |
| 15 | Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. David M. Brizel, Sean P. Scully, John M. Harrelson et al. · PubMed | Mar 1996 | 1,194 |
| 16 | Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology Margaret von Mehren et al. · Journal of the National Comprehensive Cancer Network | Jul 2022 | 1,188 |
| 17 | Terminology of nodular hepatocellular lesions Ian R. Wanless · Hepatology | Sep 1995 | 1,139 |
| 18 | Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis Francis X. McCormack et al. · New England Journal of Medicine | 16 Mar 2011 | 1,131 |
| 19 | Preoperative chemotherapy for osteogenic sarcoma:Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy Gerald Paul Rosen, Brenda Caparros, Andrew G. Huvos et al. · Cancer | 15 Mar 1982 | 1,105 |
| 20 | The implications of angiogenesis for the biology and therapy of cancer metastasis Isaiah J. Fidler · Cell | 21 Oct 1994 | 1,103 |
| 21 | Angiosarcomas Express Mixed Endothelial Phenotypes of Blood and Lymphatic Capillaries Silvana Breiteneder-Geleff, Afschin Soleiman, Heinrich Kowalski et al. · American Journal Of Pathology | Feb 1999 | 1,099 |
| 22 | Tumors of the major salivary glands Frank W. Foote, Edgar L. Frazell · Cancer | Nov 1953 | 1,094 |
| 23 | Interferon Alfa-2a Therapy for Life-Threatening Hemangiomas of Infancy R. Alan B. Ezekowitz, John Butler Mulliken, Judah Folkman · New England Journal of Medicine | 28 May 1992 | 1,079 |
| 24 | Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆ Alessandro Gronchi et al. · Annals of Oncology | 22 Jul 2021 | 1,057 |
| 25 | Ten years of anti-vascular endothelial growth factor therapy Napoleone Ferrara, Anthony P. Adamis · Nature Reviews Drug Discovery | 18 Jan 2016 | 1,049 |
| 26 | Perivascular Epithelioid Cell Neoplasms of Soft Tissue and Gynecologic Origin Andrew L. Folpe, Thomas Mentzel, Hans‐Anton Lehr et al. · The American Journal of Surgical Pathology | Dec 2005 | 996 |
| 27 | A systematic meta‐analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft‐tissue sarcoma Nabeel Pervaiz, Nigel R. Colterjohn, Forough Farrokhyar et al. · Cancer | 2 Jun 2008 | 995 |
| 28 | WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition Vickie Y. Jo, Christopher D.�M. Fletcher · Pathology | 30 Dec 2013 | 980 |
| 29 | Angiosarcoma Robin Young, Nicola Jane Brown, Malcolm Reed et al. · The Lancet Oncology | 26 May 2010 | 977 |
| 30 | Soft-Tissue Sarcomas in Adults Matthew A. Clark, Cyril Fisher, Ian Robert Judson et al. · New England Journal of Medicine | 17 Aug 2005 | 920 |
| 31 | Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial John J. Bissler, John Christopher Kingswood, Elżbieta Radzikowska et al. · The Lancet | 11 Jan 2013 | 893 |
| 32 | Rhabdomyosarcoma Stephen X. Skapek, Andrea C. Ferrari, Abha A. Gupta et al. · Nature Reviews Disease Primers | 7 Jan 2019 | 891 |
| 33 | GLUT1: A newly discovered immunohistochemical marker for juvenile hemangiomas Paula E. North, Milton Waner, Adam Mizeracki et al. · Human Pathology | 2000 | 861 |
| 34 | VEGF-receptor signal transduction Michael J Cross, Johan Dixelius, Tarô Matsumoto et al. · Trends in Biochemical Sciences | Sep 2003 | 858 |
| 35 | Tuberous sclerosis complex Elizabeth P. Henske, Sergiusz Jóźwiak, John Christopher Kingswood et al. · Nature Reviews Disease Primers | 26 May 2016 | 857 |
| 36 | Cardiac tumours: diagnosis and management JAGDISH W. BUTANY, Vidhya Nair, Ather Naseemuddin et al. · The Lancet Oncology | Apr 2005 | 852 |
| 37 | Soft Tissue Sarcomas Janice N. Cormier, Raphael E. Pollock · CA A Cancer Journal for Clinicians | Mar 2004 | 839 |
| 38 | Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Berit Olofsson, Katri Pajusola, Arja Kaipainen et al. · Proceedings of the National Academy of Sciences | 19 Mar 1996 | 830 |
| 39 | Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation Tuomas Tammela et al. · Nature | 25 Jun 2008 | 823 |
| 40 | Clinical and Molecular Features of the Carney Complex: Diagnostic Criteria and Recommendations for Patient Evaluation Constantine A. Stratakis, Lawrence Steven Kirschner, J. Aidan Carney · The Journal of Clinical Endocrinology & Metabolism | Sep 2001 | 802 |
| 41 | Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial Patrick Schöffski, Sant P. Chawla, Robert G. Maki et al. · The Lancet | 12 Feb 2016 | 782 |
| 42 | A clinical and pathological staging system for soft tissue sarcomas William O. Russell, Jonathan D. Cohen, Franz M. Enzinger et al. · Cancer | Oct 1977 | 767 |
| 43 | Photodynamic Therapy in Oncology: Mechanisms and Clinical Use Harvey Ira Pass · JNCI Journal of the National Cancer Institute | 17 Mar 1993 | 757 |
| 44 | Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions Naveen S. Vasudev, Andrew R. Reynolds · Angiogenesis | 31 Jan 2014 | 756 |
| 45 | Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002 Robert G. Maki, J. Kyle Wathen, SHREYASKUMAR R. PATEL et al. · Journal of Clinical Oncology | 29 Jun 2007 | 744 |
| 46 | VEGFs and receptors involved in angiogenesis versus lymphangiogenesis Marja K. Lohela, Maija Bry, Tuomas Tammela et al. · Current Opinion in Cell Biology | 22 Feb 2009 | 744 |
| 47 | Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML) Christian Thiede, Sina Koch, Eva Creutzig et al. · Blood | 3 Feb 2006 | 734 |
| 48 | Identification of a Natural Soluble Form of the Vascular Endothelial Growth Factor Receptor, FLT-1, and Its Heterodimerization with KDR Richard L. Kendall, Guan Wang, Kenneth A. Thomas · Biochemical and Biophysical Research Communications | Sep 1996 | 732 |
| 49 | Risk of lymphoedema following the treatment of breast cancer M W Kissin, Guidubaldo Querci della Rovere, Douglas F. Easton et al. · British journal of surgery | Jul 1986 | 721 |
| 50 | Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. Anne L. Angiolillo, Cecilia Sgadari, Dennis D. Taub et al. · The Journal of Experimental Medicine | Jul 1995 | 716 |
Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for a field when OpenAlex files it under one of the field's topics; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.